Evidence map›Paper›PMID 42308654›Full record

ArticleJACC. Advances2026

Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention.

Athanasios Feidakis, Jan Althoff, Thorsten Gietzen, Laura Marx, Caroline Hasse, Jennifer von Stein, Maria I Körber, Stephan Baldus, Roman Pfister, Christos Iliadis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Athanasios FeidakisFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany. Electronic address: athanasios.feidakis@uk-koeln.com.
Jan AlthoffFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Thorsten GietzenFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Laura MarxFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Caroline HasseFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Jennifer von SteinFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Maria I KörberFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Stephan BaldusFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Roman PfisterFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.
Christos IliadisFaculty of Medicine and University Hospital Cologne, Department III of Internal Medicine, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker for risk stratification in heart failure. However, its prognostic value and early postprocedural dynamics in patients undergoing transcatheter tricuspid valve intervention (TTVI) remain incompletely defined.

objectivesThe objective of the study was to investigate the association of baseline NT-proBNP levels and early postinterventional NT-proBNP changes with long-term all-cause mortality and symptomatic improvement after TTVI.

methodsWe analyzed a cohort of patients with severe tricuspid regurgitation undergoing TTVI. Patients were stratified according to baseline NT-proBNP tertiles. Changes in NT-proBNP between baseline and 4-week follow-up were assessed, and their association with long-term all-cause mortality was evaluated using Kaplan-Meier analysis and Cox regression. NYHA functional class improvement (≥1 class) at 4 weeks was analyzed as a secondary endpoint using logistic regression.

resultsHigher baseline NT-proBNP levels were independently associated with increased long-term all-cause mortality. Early NT-proBNP changes provided additional prognostic information: patients with increasing NT-proBNP levels at 4 weeks showed markedly worse survival, irrespective of procedural success. In contrast, baseline NT-proBNP was not associated with symptomatic improvement according to NYHA functional class at 4-week follow-up. Patients with increasing NT-proBNP levels exhibited larger right atrial volumes and higher right atrial pressures at baseline, suggesting more advanced right-sided remodeling.

conclusionsIn patients undergoing TTVI, baseline NT-proBNP levels and early postprocedural increases in NT-proBNP identify individuals at high risk for long-term mortality but do not predict symptomatic improvement. NT-proBNP reflects residual myocardial stress rather than procedural success and may aid in patient selection and early postinterventional surveillance.

Indexed as

biomarkersNT-proBNPright heart failurerisk stratificationtranscatheter tricuspid valve interventiontricuspid regurgitation

Identifiers

PMID42308654
PMCPMC13311164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.